Idorsia Q3 Loss Narrows to CHF53 Million as Revenue Rises; Proposes CHF120 Million Tryvio Partnership

Idorsia Ltd (IDIA.SW) reported a narrower third-quarter net loss of CHF53 million, or CHF0.20 per share, versus CHF86 million, or CHF0.40 per share, a year earlier, while proposing a CHF120 million commercialization partnership for hypertension drug aprocitentan, sold as Tryvio/Jeraygo. Net revenue for the quarter ended September 30, 2026, rose to CHF62 million from CHF41 million. Adjusted net loss widened to CHF44 million from CHF40 million. Quviviq sales for the nine months climbed 54% to CHF142 million. Cash and cash equivalents totaled CHF85 million as of September 30, 2026. The proposed arrangement with noteholders in Idorsia Investments SARL would fund a specialist-focused U.S. launch of aprocitentan and phased commercialization in Europe and Canada, targeting hypertension centers and nephrologists. Noteholders would contribute CHF72 million for new notes plus a 12% earn-out; Idorsia would contribute CHF48 million over two years for 30% of global aprocitentan net revenue. The proposal requires noteholder approvals anticipated by year-end. Idorsia retained its full-year 2026 Quviviq sales forecast of CHF200 million and narrowed projected operating loss guidance to approximately CHF140 million from CHF160 million. Shares were down 2.18% at CHF4.48.